Actuate Therapeutics Files for IPO

TL;DR

Actuate Therapeutics is going public, filing S-1 to raise cash.

AI Summary

Actuate Therapeutics, Inc. filed an S-1 registration statement on May 24, 2024, to register securities for a potential public offering. The company, formerly known as Apotheca Therapeutics, Inc., is incorporated in Delaware and headquartered in Fort Worth, Texas. This filing indicates their intent to raise capital through the sale of stock.

Why It Matters

This S-1 filing signals Actuate Therapeutics' intention to become a publicly traded company, which could provide them with significant capital for research and development in the pharmaceutical sector.

Risk Assessment

Risk Level: medium — As a pharmaceutical company filing an S-1, Actuate Therapeutics is likely in the early stages of development, carrying inherent risks associated with drug discovery and regulatory approval.

Key Numbers

• 333-279734 — SEC File Number (Identifies the specific SEC registration)
• 473044785 — IRS Number (Company's Employer Identification Number)

Key Players & Entities

• Actuate Therapeutics, Inc. (company) — Registrant
• Apotheca Therapeutics, Inc. (company) — Former company name
• May 24, 2024 (date) — Filing date
• Delaware (location) — State of incorporation
• Fort Worth, Texas (location) — Principal executive offices
• Daniel Schmitt (person) — President and Chief Executive Officer

FAQ

Key Financial Figures

• $1.0 billion — roducts and executed over approximately $1.0 billion in milestone value through licensing, a

Filing Documents

• tm247121-12_s1.htm (S-1) — 3465KB
• tm247121d13_ex3-1.htm (EX-3.1) — 158KB
• tm247121d13_ex3-3.htm (EX-3.3) — 42KB
• tm247121d13_ex3-4.htm (EX-3.4) — 82KB
• tm247121d13_ex3-5.htm (EX-3.5) — 183KB
• tm247121d13_ex4-2.htm (EX-4.2) — 163KB
• tm247121d13_ex10-1.htm (EX-10.1) — 365KB
• tm247121d13_ex10-2.htm (EX-10.2) — 130KB
• tm247121d13_ex10-3.htm (EX-10.3) — 20KB
• tm247121d13_ex10-4.htm (EX-10.4) — 193KB
• tm247121d13_ex10-5.htm (EX-10.5) — 69KB
• tm247121d13_ex10-6.htm (EX-10.6) — 270KB
• tm247121d13_ex10-7.htm (EX-10.7) — 75KB
• tm247121d13_ex10-8.htm (EX-10.8) — 45KB
• tm247121d13_ex10-9.htm (EX-10.9) — 130KB
• tm247121d13_ex10-10.htm (EX-10.10) — 49KB
• tm247121d13_ex10-11.htm (EX-10.11) — 94KB
• tm247121d13_ex10-12.htm (EX-10.12) — 105KB
• tm247121d13_ex21-1.htm (EX-21.1) — 2KB
• tm247121d13_ex23-1.htm (EX-23.1) — 2KB
• tm247121d13_ex99-1.htm (EX-99.1) — 29KB
• tm247121d13_ex99-2.htm (EX-99.2) — 3KB
• tm247121d13_ex99-3.htm (EX-99.3) — 3KB
• tm247121d13_ex99-4.htm (EX-99.4) — 3KB
• tm247121d13_ex-filingfees.htm (EX-FILING FEES) — 12KB
• bc_1801part-4c.jpg (GRAPHIC) — 87KB
• bc_1801part2-4c.jpg (GRAPHIC) — 67KB
• bc_1801part3b-4c.jpg (GRAPHIC) — 50KB
• bc_1801part3b2-4c.jpg (GRAPHIC) — 57KB
• bc_8moverl-4c.jpg (GRAPHIC) — 84KB
• bc_overallsurvi-4c.jpg (GRAPHIC) — 80KB
• fc_clinistud-4c.jpg (GRAPHIC) — 87KB
• fc_multimoa-4c.jpg (GRAPHIC) — 92KB
• fc_tcellnk-4c.jpg (GRAPHIC) — 104KB
• lc_elraglarit-4clr.jpg (GRAPHIC) — 40KB
• lc_elrainje-4c.jpg (GRAPHIC) — 53KB
• lc_gnp-4c.jpg (GRAPHIC) — 77KB
• lg_actuatetherape-4clr.jpg (GRAPHIC) — 10KB
• ph_mri12week-bw.jpg (GRAPHIC) — 152KB
• tb_adverseevent-4c.jpg (GRAPHIC) — 111KB
• tb_elraglusib-4c.jpg (GRAPHIC) — 109KB
• tb_patients-4c.jpg (GRAPHIC) — 111KB
• tb_route-4c.jpg (GRAPHIC) — 21KB
• tm247121d13_ex10-8img001.jpg (GRAPHIC) — 21KB
• 0001104659-24-065172.txt ( ) — 7622KB

RISK FACTORS

RISK FACTORS 13 INDUSTRY AND MARKET DATA 71

USE OF PROCEEDS

USE OF PROCEEDS 72 DIVIDEND POLICY 74 CAPITALIZATION 75

DILUTION

DILUTION 78 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 81

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 82

BUSINESS

BUSINESS 99 MANAGEMENT 148

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 158 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 169 PRINCIPAL SECURITYHOLDERS 173

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 177 SHARES ELIGIBLE FOR FUTURE SALE 184 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES FOR NON-U.S. HOLDERS 187

UNDERWRITING

UNDERWRITING 191 LEGAL MATTERS 200 EXPERTS 200 WHERE YOU CAN FIND MORE INFORMATION 200 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS F-1 You should rely only on the information contained in this prospectus. Neither we nor the underwriters have authorized anyone to provide you with different information and, if provided, such information or representations must not be relied upon as having been authorized by us or the underwriters. This prospectus shall not constitute an offer to sell or a solicitation of an offer to buy offered securities in any jurisdiction in which it is unlawful for such person to make such an offering or solicitation. You should read this prospectus together with the additional information described below under the heading "Where You Can Find More Information." We may also provide a prospectus supplement or post-effective amendment to the Registration Statement to add information to, or update or change information contained in, this prospectus. The information contained in this prospectus, or any free writing prospectus is accurate only as of its date, regardless of its time of delivery or of any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. This prospectus does not contain all of the information included in the Registration Statement. For a more complete understanding of the offering of the securities, you should refer to the Registration Statement, including its exhibits. This prospectus includes our trademarks, and trade names, including but not limited to Actuate and Actuate Therapeutics, which are protected under applicable intellectual property laws. This prospectus also may contain trademarks, service marks, trade names, and copyrights of other companies, which are the property of their respective owners. Solely for convenience, the trademarks, service marks, trade names, and copyrights referred to in this prospectus are li

View Full Filing

View this S-1 filing on SEC EDGAR